-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $5

Benzinga·05/12/2026 12:39:25
Listen to the news
Wedbush analyst Robert Driscoll maintains Eikon Therapeutics (NASDAQ:EIKN) with a Underperform and lowers the price target from $7 to $5.